Evidence map›Paper›PMID 36537814›Full record

ArticlemSystems2023

Disrupting the ArcA Regulatory Network Amplifies the Fitness Cost of Tetracycline Resistance in Escherichia coli.

Mario L Arrieta-Ortiz, Min Pan, Amardeep Kaur, Evan Pepper-Tunick, Vivek Srinivas, Ananya Dash, Selva Rupa Christinal Immanuel, Aaron N Brooks, Tyson R Shepherd, Nitin S Baliga

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Antibiotic resistance inFrontiers in microbiology · 2026
    Article
  4. Article
  5. Sequential antibiotic exposure restores antibiotic susceptibility.The Journal of antimicrobial chemotherapy · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mario L Arrieta-OrtizInstitute for Systems Biology, Seattle, Washington, USA.ORCID 0000-0002-7111-8087
Min PanInstitute for Systems Biology, Seattle, Washington, USA.
Amardeep KaurInstitute for Systems Biology, Seattle, Washington, USA.
Evan Pepper-TunickInstitute for Systems Biology, Seattle, Washington, USA.
Vivek SrinivasInstitute for Systems Biology, Seattle, Washington, USA.
Ananya DashInstitute for Systems Biology, Seattle, Washington, USA.
Selva Rupa Christinal ImmanuelInstitute for Systems Biology, Seattle, Washington, USA.
Aaron N BrooksInscripta Inc, Boulder, Colorado, USA.
Tyson R ShepherdInscripta Inc, Boulder, Colorado, USA.
Nitin S BaligaInstitute for Systems Biology, Seattle, Washington, USA.ORCID 0000-0001-9157-5974
Institute for Systems Biology · USLawrence Berkeley National Laboratory · USUniversity of Washington · US

Funding

Systems Biology CoreU19AI100627 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ULEVITCH, RICHARD J · 2012 to 2021
$49.1M
Technology CoreU19AI106761 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI SHERMAN, DAVID R, ZAK, DANIEL E · 2013 to 2017
$18.9M
Technology CoreU19AI135976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADEREM, ALAN A · 2018 to 2022
$17.0M
A systems analysis of drug tolerance in Mycobacterium tuberculosisR01AI128215 · NIAID · INSTITUTE FOR SYSTEMS BIOLOGY · PI Nitin S Baliga · 2017 to 2026
$8.8M
Site Specific Immunophenotyping Assays of COVID19 Patients to Align with NIAID National StudyR01AI141953 · NIAID · INSTITUTE FOR SYSTEMS BIOLOGY · PI BALIGA, NITIN S · 2019 to 2023
$5.7M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI141953NIAID NIH HHS R01 AI128215NIAID NIH HHS R01 AI141953NIAID NIH HHS U19 AI100627NIAID NIH HHS U19 AI106761NIAID NIH HHS U19 AI135976
6 · The paper itself

Abstract

There is an urgent need for strategies to discover secondary drugs to prevent or disrupt antimicrobial resistance (AMR), which is causing >700,000 deaths annually. Here, we demonstrate that tetracycline-resistant (Tet

Indexed as

Escherichia coliEscherichia coli ProteinsAnti-Bacterial AgentsBacterial Outer Membrane ProteinsMicrobial Sensitivity TestsRepressor ProteinsSertralineTetracyclineTetracycline ResistanceAnti-Bacterial AgentsarcA protein, E coliBacterial Outer Membrane ProteinsEscherichia coli ProteinsRepressor ProteinsSertralineTetracyclineantibiotic resistanceArcAcompensatory mechanismEscherichia coliglobal regulatory networkssystems biologytetracycline

Identifiers

PMID36537814
PMCPMC9948699
OpenAlexW4312018610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.